Ethyol Approved for Use in the UK

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 1
Volume 4
Issue 1

WEST CONSHOHOCKEN, Pa--The Medicines Control Agency, the regulatory agency for the United Kingdom, has granted a product license for the marketing of Ethyol (amifostine), manufactured by U.S. Bioscience, Inc.

WEST CONSHOHOCKEN, Pa--The Medicines Control Agency, the regulatoryagency for the United Kingdom, has granted a product license forthe marketing of Ethyol (amifostine), manufactured by U.S. Bioscience,Inc.

Ethyol is a selective cytoprotective agent indicated for the reductionof neutropenia-related infection resulting from use of the combinationof cyclophosphamide (Cytoxan, Neosar) and cisplatin (Platinol)in patients with advanced ovarian carcinoma.

Approval of ethyol in this country suffered a set back when anadvisory committee failed to recommend it to the FDA.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Related Content